aTyr Pharma published Phase 3 EFZO-FIT™ study results showing efzofitimod improved patient-reported outcomes in pulmonary sarcoidosis, a serious lung disease. Although the drug did not significantly reduce steroid use compared to placebo, it enhanced quality of life measures and maintained lung function with good safety. This study is the largest of its kind and may change treatment approaches for sarcoidosis. aTyr plans further development of efzofitimod based on these findings.
aTyr Pharma's Phase 3 EFZO-FIT™ study results provide context for health sector trading on Pluang. As of Oct 29, 2026 18:11 WIB, 95 of 150 priced health-sector US stocks rose while 47 fell. Novartis AG (NVS) traded at USD 160.96 with a 3.13% gain and a typical hold time of 84 days, contrasting with Sana Biotechnology Inc (SANA) at USD 2.71, up 3.04% but with 96% sell order activity and a shorter hold time of 25 days. Gilead Sciences, Inc. (GILD) showed a price of USD 163.65, up 2.80%, with strong buy interest (87%) and a longer hold time of 114 days.
Naples Comprehensive Health (NCH) has completed the first tricuspid valve repair in the US using the PASCAL Precision system following FDA approval. This minimally invasive catheter-based procedure offers a new treatment option for patients with seve...
Immunocore Holdings will present Phase 1/2 clinical trial data for brenetafusp alone and combined with KIMMTRAK in treating metastatic uveal melanoma at the 2026 Society for Immunotherapy of Cancer meeting. This trial evaluates safety and efficacy in...
Collegium Pharmaceutical and Boston Legacy FC have extended their partnership to include youth coach training, an annual Sports for All Summit, and sensory inclusion programs aimed at supporting neurodivergent children, especially those with ADHD, in...
Gilat Satellite Networks announced that its CEO Adi Sfadia and CFO Gil Benyamini will attend the Deutsche Bank Global Space and Defense Tech Summit on November 18, 2026, in New York City. The event will feature one-on-one and group meetings, providin...
Boralex Inc. has acquired Wind2, a UK-based renewable energy developer with about 350 MW of advanced wind projects across Scotland, England, and Wales. This acquisition strengthens Boralex's presence and capabilities in the UK, aligning with its stra...
